Ministry of Healthcare of Republic of Kazakhstan
Yes
Kazakhstan is a member of the Eurasian Economic Union and thus, issues associated with the state registration of medicinal products in Kazakhstan are regulated by the Decision of the Council of the Eurasian Economic Commission. Strict guidelines are established by the EEC for drug registration. This covers, among other things, standards for labeling, packaging, quality control, and clinical studies.
A Market Authorization Holder (MAH) is a crucial component in streamlining the medication registration procedure in the dynamic and quickly changing pharmaceutical market of the European Union (EAEU). An individual or a business can take on this position; they are not required to be citizens of an EAEU member state. In essence, the MAH is in charge of guaranteeing the efficacy and safety of the medications they manufacture or supply throughout the union.
In the EAEU, the mutual recognition mechanism provides a quick and easy way to get drug approval. The registration dossier and other required documents are sent to the Competent Authority (CA) after the Market Authorization Holder (MAH) chooses a reference state.
In about two weeks, the CA reviews the records in order to determine whether to move forward with a full investigation. This comprehensive examination examines the trial results in conjunction with the medical product’s quality, safety, and efficacy. The authorities have the right to examine medicine samples for quality and do an ad hoc examination of production sites if they think it is required.
After the roughly six-month-long evaluation process, the CA drafts an expert report and decides whether to approve or deny the Market Authorization Application (MAA) for the medicine. An additional two weeks are spent in this decision-making process. The procedure can take up to 210 calendar days in total, though it may be extended if the CA asks for more details.
A five-year registration certificate is provided following market approval. Every EAEU member state uses the same model for this certificate. The validity of the certificate usually lasts forever upon re-registration.
Within the European Union, a different route to market authorization is provided by the decentralized medication registration process. This approach entails simultaneously submitting an MAA to multiple EAEU members, if not all of them.
In this process, most administrative procedures are handled by one member state, designated as the reference. This reference state is frequently selected according to criteria like its market size, regulatory ability, or significance to the drug’s therapeutic area.
The evaluation is carried out by the reference state, and the other states to which the application has been submitted are informed of its results. The marketing permission is granted by the reference state and confirmed by all participating states if no objections are raised by the other states.
When a business want to simultaneously introduce a product into several EAEU nations, it frequently takes this route. Getting extensive market authorization through this method can be quicker and more effective than applying separately for each state.
By streamlining the EAEU’s drug registration system, both of these measures hope to facilitate MAHs’ efforts to introduce safe and effective medications onto the market. Any pharmaceutical business or individual wishing to navigate the drug registration landscape in the European Union must have a thorough understanding of these channels.
1. Application Form
2. Normative Document
3. Quality Document
4. Clinical Documents
5. Non-Clinical Documents
6. Legalized Power of Attorney from the applicant to the representative.
7. Legalized copies of Manufacturer’s Authorizations for all manufacturing sites involved in the manufacturing process issued by the competent authorities of countries-manufacturers.
8. Legalized copies of GMP Certificates for all manufacturing sites involved in the manufacturing process issued by the competent authorities of countries-manufacturers.
In accordance with the requirements of the EAEU, the state registration process for a medicinal product must be completed in 140 working days, not including the time needed to prepare responses to requests. However, as is customary, the registration process may take anywhere between 12 and 18 months, not including the time needed to prepare responses to requests, depending on the extent of the documentation provided, the number of requests sent by the National Center for Expertise of Medicines and Medical Devices, and other factors.
According to EAEU legislation, the process of state registration of a medicinal product permits the centralized recognition of the state registration in another EAEU member state following the issuance of the Eurasian Certificate, thereby facilitating a simplified state registration of said medicinal product in other EAEU member states.
Alternatively, the medicinal product may be applied for a simplified state registration in another EAEU member state without first needing approval for registration in the first reference country. In this scenario, however, the application for state registration in another EAEU member state must be submitted to the appropriate authority within 14 working days of the date of the initial state registration filing.
The Eurasian Certificate, which was granted in compliance with Eurasian Economic Union legislation, regarding the state registration of medicinal products in Kazakhstan, is perpetually valid. Nevertheless, within five years of a medicine’s initial registration in Kazakhstan, it must be renewed. The process of renewing a registration can begin prior to the previous registration’s expiration date, but no earlier than 140 working days.
When the period for preparing responses to remarks is not considered, the typical renewal procedure takes roughly six months. The quality, preclinical, and clinical data verification is not required for the renewal procedure; nevertheless, reports from independent experts in the form of Module 2 of the standard technical document (CTD) on quality and current benefit/risk balance for the product on the basis of safety/efficacy data accumulated since the first registration, making reference to relevant new information in the public domain.
12-18 months
5 years
Our team will be happy to respond your queries. Contact us directly with your questions or for scheduling FREE consultation and we’ll be in touch as soon as possible.
Our team will be happy to respond your queries. Contact us directly with your questions or for scheduling FREE consultation and we’ll be in touch as soon as possible.
Our team will be happy to respond your queries. Contact us directly with your questions or for scheduling FREE consultation and we’ll be in touch as soon as possible.
To launch a medical device in a country, medical devices must comply with the local country’s regulatory requirements. Let us be your trusted partner in bringing your medical devices to the Global market. Contact us today to learn more about how we can assist you in every step of the way.
This will close in 0 seconds